iRhythm Technologies, Inc. Class Action Lawsuit - IRTC

According to the lawsuit, defendants falsely represented to investors that one of iRhythm’s main products, the Zio AT monitor, was a real-time heart monitor intended for high-risk patients. Specifically, defendants repeatedly touted the potential growth for the Zio AT as an innovative product that had only just begun to penetrate the market for real-time monitoring, which investors looked upon favorably given the premium selling price associated with devices approved for high-risk patients. As a result of these misrepresentations, the price of iRhythm common stock traded at artificially inflated prices throughout the class period.

In order to be eligible to join the IRTC class action lawsuit, you must have incurred a loss on shares of iRhythm Technologies purchased during the class period listed above.

If you suffered a loss in iRhythm Technologies during the relevant time frame or pursuant to the relevant offering(s), you have until April 8, 2024 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.